BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 21982726)

  • 41. No metabolic impact of surgical normalization of hyperandrogenism in postmenopausal women with ovarian androgen-secreting tumours.
    Pelusi C; Forlani G; Zanotti L; Gambineri A; Pasquali R
    Clin Endocrinol (Oxf); 2013 Apr; 78(4):533-8. PubMed ID: 22583337
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reconciling the definitions of polycystic ovary syndrome: the ovarian follicle number and serum anti-Müllerian hormone concentrations aggregate with the markers of hyperandrogenism.
    Dewailly D; Pigny P; Soudan B; Catteau-Jonard S; Decanter C; Poncelet E; Duhamel A
    J Clin Endocrinol Metab; 2010 Sep; 95(9):4399-405. PubMed ID: 20610596
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Influence of adrenal hyperandrogenism on the clinical and metabolic phenotype of women with polycystic ovary syndrome.
    Alpañés M; Luque-Ramírez M; Martínez-García MÁ; Fernández-Durán E; Álvarez-Blasco F; Escobar-Morreale HF
    Fertil Steril; 2015 Mar; 103(3):795-801.e2. PubMed ID: 25585504
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cross-sectional analysis of the effects of age on the hormonal, metabolic, and ultrasonographic features and the prevalence of the different phenotypes of polycystic ovary syndrome.
    Panidis D; Tziomalos K; Macut D; Delkos D; Betsas G; Misichronis G; Katsikis I
    Fertil Steril; 2012 Feb; 97(2):494-500. PubMed ID: 22192350
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association of biochemical hyperandrogenism with type 2 diabetes and obesity in Chinese women with polycystic ovary syndrome.
    Zhao X; Zhong J; Mo Y; Chen X; Chen Y; Yang D
    Int J Gynaecol Obstet; 2010 Feb; 108(2):148-51. PubMed ID: 19932893
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study.
    Valkenburg O; Steegers-Theunissen RP; Smedts HP; Dallinga-Thie GM; Fauser BC; Westerveld EH; Laven JS
    J Clin Endocrinol Metab; 2008 Feb; 93(2):470-6. PubMed ID: 18056772
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fatty acid-binding protein-4 plasma levels are associated to metabolic abnormalities and response to therapy in girls and young women with androgen excess.
    Lázaro I; Díaz M; Cabré A; Masana L; Ibáñez L
    Gynecol Endocrinol; 2011 Nov; 27(11):935-9. PubMed ID: 21605000
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serum calcitonin gene-related peptide levels in women with polycystic ovary syndrome.
    Fenkci SM; Fenkci V; Oztekin O; Rota S
    Arch Gynecol Obstet; 2013 Jun; 287(6):1235-9. PubMed ID: 23263174
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Age-related differences in the reproductive and metabolic implications of polycystic ovarian syndrome: findings in an obese, United States population.
    Johnstone EB; Davis G; Zane LT; Cedars MI; Huddleston HG
    Gynecol Endocrinol; 2012 Oct; 28(10):819-22. PubMed ID: 22475130
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Smoking is associated with increased free testosterone and fasting insulin levels in women with polycystic ovary syndrome, resulting in aggravated insulin resistance.
    Cupisti S; Häberle L; Dittrich R; Oppelt PG; Reissmann C; Kronawitter D; Beckmann MW; Mueller A
    Fertil Steril; 2010 Jul; 94(2):673-7. PubMed ID: 19394003
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Polycystic ovaries in nonobese adolescents and young women with ovarian androgen excess: relation to prenatal growth.
    Ibáñez L; López-Bermejo A; Callejo J; Torres A; Cabré S; Dunger D; de Zegher F
    J Clin Endocrinol Metab; 2008 Jan; 93(1):196-9. PubMed ID: 17956949
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of adrenal versus ovarian androgen ratio on signs and symptoms of polycystic ovarian syndrome.
    Köşüş N; Köşüş A; Kamalak Z; Hızlı D; Turhan NÖ
    Gynecol Endocrinol; 2012 Aug; 28(8):611-4. PubMed ID: 22296561
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Menstrual disorders in adolescence: a marker for hyperandrogenaemia and increased metabolic risks in later life? Finnish general population-based birth cohort study.
    Pinola P; Lashen H; Bloigu A; Puukka K; Ulmanen M; Ruokonen A; Martikainen H; Pouta A; Franks S; Hartikainen AL; Järvelin MR; Morin-Papunen L
    Hum Reprod; 2012 Nov; 27(11):3279-86. PubMed ID: 22933528
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Randomized comparison of the influence of dietary management and/or physical exercise on ovarian function and metabolic parameters in overweight women with polycystic ovary syndrome.
    Nybacka Å; Carlström K; Ståhle A; Nyrén S; Hellström PM; Hirschberg AL
    Fertil Steril; 2011 Dec; 96(6):1508-13. PubMed ID: 21962963
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The influence of obesity on androstenedione to testosterone ratio in women with polycystic ovary syndrome (PCOS) and hyperandrogenemia.
    Misichronis G; Georgopoulos NA; Marioli DJ; Armeni AK; Katsikis I; Piouka AD; Saltamavros AD; Roupas ND; Panidis D
    Gynecol Endocrinol; 2012 Apr; 28(4):249-52. PubMed ID: 21970600
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Vitamin D as a predictor of insulin resistance in polycystic ovarian syndrome.
    Patra SK; Nasrat H; Goswami B; Jain A
    Diabetes Metab Syndr; 2012; 6(3):146-9. PubMed ID: 23158978
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Androgens and antimüllerian hormone in mothers with polycystic ovary syndrome and their newborns.
    Vanky E; Carlsen SM
    Fertil Steril; 2012 Feb; 97(2):509-15. PubMed ID: 22154766
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oligo-ovulation or anovulation and hyperandrogenemia contribute to the decreased serum adiponectin levels in normal-weight women with PCOS with obesity and insulin resistance.
    Katsikis I; Mouslech T; Kourtis A; Panidis D; Georgopoulos NA
    Fertil Steril; 2009 Apr; 91(4):e3; author reply e4. PubMed ID: 19243758
    [No Abstract]   [Full Text] [Related]  

  • 59. Hyperandrogenism in adolescent girls with type 1 diabetes mellitus treated with intensive and continuous subcutaneous insulin therapy.
    Zachurzok A; Deja G; Gawlik A; Drosdzol-Cop A; Małecka-Tendera E
    Endokrynol Pol; 2013; 64(2):121-8. PubMed ID: 23653275
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prevalence of hyperandrogenism and polycystic ovary syndrome in female to male transsexuals.
    Becerra-Fernández A; Pérez-López G; Román MM; Martín-Lazaro JF; Lucio Pérez MJ; Asenjo Araque N; Rodríguez-Molina JM; Berrocal Sertucha MC; Aguilar Vilas MV
    Endocrinol Nutr; 2014; 61(7):351-8. PubMed ID: 24680383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.